Skip to main content

IVA · Inventiva S.A.

Track IVA — free
$3.14 -0.31 (-8.99%) At close · Nov 20
Market Cap
$750.78M
Shares
239.10M
Volume · Nov 20 3.02M Avg daily vol (3M) 2.37M

Price & Indicators

 

Key stats

Close
$3.14
Fri 20 Nov
Open
$3.44
Fri 20 Nov
Average volume, 30 days
2.8M
shares a session
Short interest
10.3M
4.3% of shares · 3.5 days to cover
Day range
$3.13$3.44
Open $3.44 Close $3.14
52-week closing range
$2.87$7.15
Close $3.14 56.1% under the high
Short volume, last session
43%
Last earnings
Sep 28, 2026
Price history
Jul 2020 to Nov 2026

Up next

Jun 30, 2027 Est · unconfirmed · in 31 wks

Latest documents

2026
Oct 6
Current report 6-K
Current report

Inventiva will present three abstracts at AASLD The Liver Meeting® 2026, held November 5-9, 2026, in Denver, Colorado, concerning lanifibranor in MASH. Phase 3 NATiV3 topline results are expected in the fourth quarter of this year.

Sep 28
Current report 6-K
Current report

Inventiva S.A. completed a June 2026 refinancing, drew €75.0 million, had €166.1 million in cash and cash equivalents at June 30, 2026, and completed NATiV3’s final patient visit, targeting topline results in the fourth quarter of 2026.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$57,158
Trailing 12 months
Net income (TTM)
−$288.97M
Trailing 12 months
Revenue growth YoY
-51.3%
Year over year
Operating margin
-302,981.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+102.0%
Year over year · more shares
Price change (1Y)
-19.1%
Trailing year
Short interest
4.3%
Latest settlement · 3.5 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −33%
below
Price vs 50-day avg −11%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 6%
near low
Momentum
relative strength
Very Weak
1-month return −15%
trailing
6-month return −23%
trailing
YTD return −32%
this year
Relative strength −14%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+13% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.33% of shares out · ▲ +26.9% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
99 holders — near 3-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 66%
annualized · 1-yr
Max drawdown −60%
past year
ATR 9.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−33% Bearish
Price vs 50-day avg
−11% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
6% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+13% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.33% of shares out · ▲ +26.9% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
99 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $3 · 6% Range high $7
vs 200-day avg -33% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IVA
Inventiva S.A.
this stock
$750.78M -32.5% — — 4.3%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
99
% held
39.4%
Net QoQ
+9.6M sh
Top holder
Caligan Partners LP
Held Float
View
Held by Funds
Fund positions
14
View
Short & Settlement
Short Interest Rising
Shares short
10.3M
Days to cover
3.5d
Change
+2.2M sh
View
Short Volume
Short vol %
43%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
5.2K
Value
$19.3K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
55.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 6, 2026
This year
20

Inventiva will present three abstracts at AASLD The Liver Meeting® 2026, held November 5-9, 2026, in Denver, Colorado, concerning lanifibranor in MASH. Phase 3 NATiV3 topline results are expected in the fourth quarter of this year.

View
Earnings & Events
Webcasts
Last webcast
Sep 28, 2026
View
Investor Relations
Latest news
Inventiva to Present Scientific A…
Published
Oct 6, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
IVA -14.7% -15.4% -23.2% -14.0% -32.5%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -6.1% -6.1% -14.1% -5.3% -33.6%
Key facts CIK 1756594 CUSIP 46124U107 13F (30d) 93 filings 92 filers Visit website Investor relations